Issue

Vol. 65 No. 7: Issue 7

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines

https://doi.org/10.14715/cmb/2019.65.7.6
Roula Tahtouh
Cancer and Metabolism Laboratory, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon
Layal Wardi
Cancer and Metabolism Laboratory, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon
Riad Sarkis
Faculty of Medicine, Saint-Joseph University and Hotel-Dieu de France, Surgery Department, Beirut, Lebanon
Ray Hachem
Department of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Issam Raad
Department of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Nabil El Zein
Life & Earth Sciences department, Faculty of Sciences, Lebanese University, Beirut, Lebanon
George Hilal
Cancer and Metabolism Laboratory, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon

Corresponding Author(s) : George Hilal

george.hilal@usj.edu.lb

Cellular and Molecular Biology, Vol. 65 No. 7: Issue 7

Abstract

Aerobic glycolysis, known as the "Warburg effect”, is one of several hallmarks of cancer cells. The conversion of phosphoenolpyruvate (PEP) to pyruvate can be down regulated by the re-expression of the embryonic isoform 2 of pyruvate kinase (PKM2). This mechanism allows the accumulation of glycolytic intermediates for the biosynthesis of macromolecules, such as proteins, lipids and nucleic acids. PKM2 is favored by the well-known PI3K/Akt/mTOR proliferative pathway. This pathway is induced by high glucose levels, and the mTOR kinase is the central activator of the Warburg effect. In this study, we investigated the role of glucose restriction (GR) and mTOR inhibition  in reversing the Warburg effect in MDA-MB 231 and MCF-7 breast cancer cell lines. PKM2 expression was measured by western blot. Lactate production by cells was determined by a colorimetric assay. The concentration of glucose in the supernatant of cells was measured using the Trinder method. ATP level  was evaluated by using a Colorimetric/Fluorometric ATP Assay Kit. Our results showed that MDA-MB 231 cells increased glucose consumption when the glucose concentration was 0 g/L (P <0.01). In MCF-7 cells, glucose deprivation reduced lactate secretion by 80% (P =0.0001) but tripled glucose consumption (P = 0.0041). ATP concentration increased approximately when MCF-7 cells were deprived of glucose (P = 0.02). GSK1059615 does not significantly modulate lactate secretion and glucose uptake in both cell lines. Glucose restriction contribute to the reduction of the Warburg effect through mTOR inhibition and regulation of PKM2 kinases.

Keywords

Glucose restriction PKM2 mTOR MDA-MB 231 MCF-7 GSK1059615.
Tahtouh, R., Wardi, L., Sarkis, R., Hachem, R., Raad, I., El Zein, N., & Hilal, G. (2019). Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines. Cellular and Molecular Biology, 65(7), 26–33. https://doi.org/10.14715/cmb/2019.65.7.6
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Warburg O, Wind F, Negelein E. THE METABOLISM OF TUMORS IN THE BODY. J. Gen. Physiol. 1927;8:519–30.
  2. Parks SK, Chiche J, Pouysségur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer. 2013;13:611–23.
  3. Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, et al. The impact of 18F-FDG PET/CT in patients with liver metastases. Eur. J. Nucl. Med. Mol. Imaging. 2007;34:1906–14.
  4. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.
  5. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 2010;207:339–44.
  6. Noguchi T, Yamada K, Yamagata K, Takenaka M, Nakajima H, Imai E, et al. Expression of liver type pyruvate kinase in insulinoma cells: involvement of LF-B1 (HNF1). Biochem. Biophys. Res. Commun. 1991;181:259–64.
  7. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011;43:969–80.
  8. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 2010;329:1492–9.
  9. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry (Mosc.). 2005;44:9417–29.
  10. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463:364–8.
  11. Macintyre AN, Rathmell JC. PKM2 and the tricky balance of growth and energy in cancer. Mol. Cell. 2011;42:713–4.
  12. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145:732–44.
  13. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–62.
  14. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2004;10:2846–50.
  15. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2001;7:3269–75.
  16. Bellizzi AM, Bloomston M, Zhou X-P, Iwenofu OH, Frankel WL. The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis. Appl. Immunohistochem. Mol. Morphol. AIMM Off. Publ. Soc. Appl. Immunohistochem. 2010;18:442–7.
  17. Schäfer D, Hamm-Künzelmann B, Hermfisse U, Brand K. Differences in DNA-binding efficiency of Sp1 to aldolase and pyruvate kinase promoter correlate with altered redox states in resting and proliferating rat thymocytes. FEBS Lett. 1996;391:35–8.
  18. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 1996;271:31372–8.
  19. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. U. S. A. 2001;98:136–41.
  20. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2011;108:4129–34.
  21. Gupta V, Bamezai RNK. Human pyruvate kinase M2: a multifunctional protein. Protein Sci. Publ. Protein Soc. 2010;19:2031–44.
  22. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012;150:685–96.
  23. Filipp FV. Cancer metabolism meets systems biology: Pyruvate kinase isoform PKM2 is a metabolic master regulator. J. Carcinog. 2013;12:14.
  24. Hammerman PS, Fox CJ, Thompson CB. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem. Sci. 2004;29:586–92.
  25. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell. 2011;42:719–30.
  26. He X#1, Du S#2, Lei T#2, Li X#2, Liu Y3, Wang H4, Tong R1, Wang Y PKM2 in carcinogenesis Oncotarget. 2017 Nov 20;8(66):110656-110670
  27. Shen L1, O'Shea JM2, Kaadige MR2, Cunha S2, Wilde BR2, Cohen AL3, Welm AL2, Ayer DE4. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5425-30
  28. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.
  29. De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzúa P, Vatner SF, Rabson AB. Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis. 2011;32:1381–7.
  30. Saleh AD, Simone BA, Palazzo J, Savage JE, Sano Y, Dan T, et al. Caloric restriction augments radiation efficacy in breast cancer. Cell Cycle Georget. Tex. 2013;12:1955–63.
  31. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–5.
  32. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res. Treat. 2011;126:355–64.
  33. Liu B, Fan Z, Edgerton SM, Deng X-S, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle Georget. Tex. 2009;8:2031–40.
  34. Jing Tan , Qiang Yu Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy. Chin J Cancer. 2013 Jul; 32(7): 376–379.
  35. Yun CW, Lee SH The Roles of Autophagy in Cancer Int J Mol Sci. 2018 Nov 5;19(11).
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1285 Download : 548